GABA reuptake inhibitor (antiepileptic)
Tiagabine
Brand names: Gabitril
Adult dose
Dose: Initial 5mg PO BD with food, increase by 5–10mg/week; usual 30–45mg/day
Route: PO
Frequency: BD-TDS
Clinical pearls
- Adjunct for partial seizures
- Take with food
Contraindications
- Severe hepatic impairment
- Hypersensitivity
Side effects
- Dizziness
- Asthenia
- Tremor
- Depression
- Confusion
- Non-convulsive status epilepticus (rare)
Interactions
- Enzyme inducers (raise tiagabine clearance)
- CNS depressants
Monitoring
- Mood
- Seizures
- LFTs
Reference: BNF; NICE NG217; https://bnf.nice.org.uk/drugs/tiagabine/. Verify against your local formulary and the latest BNF before prescribing.
Related
Curated clinical cross-links plus same-class fallbacks.
Calculators
- SMART Risk Score for Recurrent CVD · Cardiovascular Risk
- PCSK9 Inhibitor Eligibility Assessment · Lipid Management
- Immune-Related Adverse Events (irAE) -- GI Toxicity Colitis Grading · Oncology-Related GI
- irAE Hepatitis Grading (CTCAE) · Immunotherapy
- DIPSS — Dynamic International Prognostic Scoring System for Myelofibrosis · Cancer Prognosis
- BALL Score for Relapsed/Refractory CLL · Leukaemia
Pathways
- Acute Stroke / TIA Assessment · NICE NG128; RCP Stroke Guidelines 2023
- Status Epilepticus (Adults) · NICE CG137; ESEM guidelines; RCP Neurology Guidelines
- Suspected Subarachnoid Haemorrhage · NICE NG228; RCEM 2023; AHA/ASA 2023
- Adult Head Injury · NICE NG232 (2023)
- Bell's Palsy / Facial Nerve Palsy · ENT UK 2017; AAN
- Vertigo Workup · ENT UK; NICE CKS